NYBC Ventures: Funding, Team & Investors | Startup Intros

Loading organizations...

NYBC Ventures: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Mar 10, 2026	Vitestro	$70.0M Series B	—	Fred Moll, M.D, EIC Fund, InterVest, Megann Vaughn Watters, Mayo Clinic, McPike Global Family Office, PGGM, Puma Venture Capital, ROM Utrecht Region, Fred Moll, M.D, Sutter Health
Dec 16, 2025	Cellular Origins	$40.0M Series A	Johnson & Johnson Innovation	Luke Rajah, Sam Hyde, Laurence Garrett
Jun 3, 2025	Akadeum Life Sciences	$20.0M Other Equity	Paul Damato	Dan Kidle
Apr 1, 2024	Vitestro	$21.0M Series A	Sonder Capital, NYBC Ventures	Nimit Maru, EIC Fund
Sep 1, 2023	Star Therapeutics	$90.0M Series C	Sofinnova Investments	Foresite Capital, OrbiMed, Sanofi Ventures, Versant Ventures, Westlake Village BioPartners, Agent Capital, Catalio Capital Management, Cormorant Asset Management, Cowen Healthcare Investments, Vijay Lathi, Qatar Investment Authority, Matthew Hammond, Amrit Nagpal, Soleus Capital
Jun 20, 2023	Veralox Therapeutics	$24.0M Other Equity	—	Genesys Capital, Hatteras Venture Partners, JDRF T1D Fund, Meg Wood, Peter Young, Sanofi Ventures
Feb 1, 2023	Thymmune Therapeutics	$7.0M Seed	Thomas de Vlaam	Catalio Capital, Flagship Ventures, Third Rock Ventures, George Church, James Fordyce, John Maraganore, Judy Pagliuca, Mark Bamforth OBE, Philip Reilly, Christopher D. Hillyer